AUG 25, 2021 10:00 AM PDT

Sino Biological's Listing on the Shenzhen Stock Exchange

SPONSORED BY: Sino Biological

China, August 16, 2021 - Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company which provides biological research reagents and related technical contract research services, announced a successful listing on the Shenzhen Stock Exchange subsidiary ChiNext under the stock abbreviation Sino Biological and stock code 301047. A total of 17 million shares were issued for a total of 4.98 billion RMB raised during this initial public offering.

Sino Biological's successful listing on the capital market is an important milestone in its strategic plan for growth. While justifying its current business model and portfolio, this offering also conveys a new starting point for the company’s future growth and development, providing the financial backing for broad and rapid expansion of Sino Biological’s existing capabilities. Dr. Liangzhi Xie, Chairman of Sino Biological, expressed in his speech at the listing ceremony that, through this offering, “Sino Biological will now be able to further enhance its strength in as one of the world’s leading providers of research reagents and services, while simultaneously improving its competitiveness and profitability. These endeavors will bring multiple benefits to investors such as increased shareholder value while positively impacting the health and well-being of society.”

The Listing Ceremony

As a high-tech enterprise, Sino Biological specializes in the research, development, production and sales of biological reagents such as recombinant proteins, antibodies, genes and culture media.  The company also provides related technical contract research services, including the development of recombinant proteins and antibodies as well as biological analysis and testing. With a number of advanced core technologies, Sino Biological has established a complete technology platform covering research, development, scale-up production, and quality control so as to guarantee the high-throughput and efficient generation of biological reagents. Currently, Sino Biological manufactures and sells more than 47,000 varieties of off-the-shelf products, including more than 6,000 varieties of recombinant proteins and more than 13,000 varieties of antibodies.  These products cover numerous different fields of life science research thereby providing a comprehensive channel for the "one-stop" procurement of biological reagent products and related technical research services.  The company’s offering helps to drive advances in the understanding of such fields as molecular biology, cell biology, immunology, developmental and stem cell biology and promotes the research and development of innovative drugs and diagnostic tests.

In the future, Sino Biological will broaden efforts in the innovation, expansion and optimization of existing product and service lines.  This will be accomplished through internal development and acquisition of key technologies coupled with aggressive infrastructure growth, which will enhance the company’s core competitiveness and drive towards fulfilling Sino Biological’s mission to advance life science and improve human health.

About Sino Biological

Sino Biological is an international biological reagent supplier and service provider. The company specializes in recombinant antigen production and antibody development. The company’s ever-growing portfolio of products includes recombinant proteins, monoclonal antibodies, ELISA assay kits, expression clones, cell culture media, and other molecular biology tools. The company also offers a variety of customized services, mainly focusing on recombinant production of antigens and antibodies. Sino Biological is dedicated to virology and infectious disease research. Its newly launched ProVirTM collection is the world’s largest viral antigen bank, carrying over 1000 products from 350 strains of viruses.

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, over which Biological has no control. Sino Biological assumes no obligation to update these forward-looking statements and do not intend to do so. More information about these factors is contained in Sino Biological's filings with the Shenzhen Stock Exchange.

 

Contacts:

Sino Biological, Inc.

ir@sinobiological.cn

www.sinobiological.com

 
About the Sponsor
  • Sino Biological is an internationally-recognized reagent supplier and contract research organization. As a global leader in recombinant technology, it specializes in recombinant protein production and antibody development. All of Sino Biological’s products are independently developed and produced, including 6,000+ recombinant proteins and 13,000+ antibodies. The company has developed the world’s largest recombinant viral antigen bank, ProVir™.
You May Also Like
OCT 18, 2021
Genetics & Genomics
A Decade After Gene Therapy, SCID Patients Are Doing Well
OCT 18, 2021
A Decade After Gene Therapy, SCID Patients Are Doing Well
For decades, scientists have been trying to find ways to cure disorders that can be traced back to an error in one gene. ...
NOV 08, 2021
Cell & Molecular Biology
Understanding How Problems in Bone Marrow Transplants Arise
NOV 08, 2021
Understanding How Problems in Bone Marrow Transplants Arise
The hematopoietic system is how new blood cells are formed; hematopoietic stem cells in bone marrow generate new hematop ...
NOV 10, 2021
Genetics & Genomics
A Protein That Helps Mitochondria Get the Antioxidants They Need
NOV 10, 2021
A Protein That Helps Mitochondria Get the Antioxidants They Need
Energy can come at a cost. In the body, as energy is produced in our cells, those essential chemical reactions also gene ...
NOV 22, 2021
Health & Medicine
Important Considerations in the Humanization of Antibodies
NOV 22, 2021
Important Considerations in the Humanization of Antibodies
In therapeutic applications, monoclonal antibodies (mAbs) provide highly precise targeting of pathological cells and red ...
NOV 24, 2021
Cardiology
Stressed Mitochondria From Fat Cells Are a Warning to the Heart
NOV 24, 2021
Stressed Mitochondria From Fat Cells Are a Warning to the Heart
While obesity is closely linked to cardiovascular disease, that connection is murky. Some people who are considered obes ...
NOV 25, 2021
Microbiology
How Microbes Use Copper to Make an Antibiotic
NOV 25, 2021
How Microbes Use Copper to Make an Antibiotic
Copper is known to have antibacterial properties, and though it's an important chemical for many organisms, it can b ...
Loading Comments...